BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 17545544)

  • 1. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.
    Guida T; Anaganti S; Provitera L; Gedrich R; Sullivan E; Wilhelm SM; Santoro M; Carlomagno F
    Clin Cancer Res; 2007 Jun; 13(11):3363-9. PubMed ID: 17545544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
    Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
    Guo T; Agaram NP; Wong GC; Hom G; D'Adamo D; Maki RG; Schwartz GK; Veach D; Clarkson BD; Singer S; DeMatteo RP; Besmer P; Antonescu CR
    Clin Cancer Res; 2007 Aug; 13(16):4874-81. PubMed ID: 17699867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M; Nguyen TK; Dent P; Grant S
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
    Klein M; Schermuly RT; Ellinghaus P; Milting H; Riedl B; Nikolova S; Pullamsetti SS; Weissmann N; Dony E; Savai R; Ghofrani HA; Grimminger F; Busch AE; Schäfer S
    Circulation; 2008 Nov; 118(20):2081-90. PubMed ID: 18955668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
    Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate).
    Mukherjee J; Kamnasaran D; Balasubramaniam A; Radovanovic I; Zadeh G; Kiehl TR; Guha A
    Cancer Res; 2009 Jun; 69(12):5099-107. PubMed ID: 19509233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
    Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
    Negri T; Pavan GM; Virdis E; Greco A; Fermeglia M; Sandri M; Pricl S; Pierotti MA; Pilotti S; Tamborini E
    J Natl Cancer Inst; 2009 Feb; 101(3):194-204. PubMed ID: 19176456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
    Adnane L; Trail PA; Taylor I; Wilhelm SM
    Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
    Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
    Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice.
    Knight B; Tirnitz-Parker JE; Olynyk JK
    Gastroenterology; 2008 Sep; 135(3):969-79, 979.e1. PubMed ID: 18602920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.
    Lierman E; Lahortiga I; Van Miegroet H; Mentens N; Marynen P; Cools J
    Haematologica; 2007 Jan; 92(1):27-34. PubMed ID: 17229632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours?
    Liegl B; Leithner A; Bauernhofer T; Windhager R; Guelly C; Regauer S; Beham A
    Histopathology; 2006 Dec; 49(6):576-81. PubMed ID: 17163842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
    Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
    Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
    Bauer S; Duensing A; Demetri GD; Fletcher JA
    Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate.
    Kosmider O; Denis N; Dubreuil P; Moreau-Gachelin F
    Oncogene; 2007 May; 26(26):3904-8. PubMed ID: 17173066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
    Wolff NC; Randle DE; Egorin MJ; Minna JD; Ilaria RL
    Clin Cancer Res; 2004 May; 10(10):3528-34. PubMed ID: 15161712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.